Travere therapeutics announces confirmatory data from the phase 3 protect study of filspari® demonstrating long-term kidney function preservation in iga nephropathy; narrowly missing egfr total slope endpoint versus active control, irbesartan

San diego, sept. 21, 2023 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced topline two-year confirmatory secondary endpoint results from the company's pivotal head-to-head phase 3 protect study of filspari® (sparsentan) in iga nephropathy (igan) versus irbesartan. filspari demonstrated long-term kidney function preservation and achieved a clinically meaningful difference in estimated glomerular filtration rate (egfr) total and chronic slope versus irbesartan, narrowly missing statistical significance in egfr total slope while achieving statistical significance in egfr chronic slope for purposes of regulatory review in the eu. filspari is currently available under accelerated approval in the u.s. the company will engage with regulators and expects to submit a supplemental new drug application (snda) in 1h 2024 for full approval in the u.s.
TVTX Ratings Summary
TVTX Quant Ranking